Tonghua Jinma announced that on August 6, 2026, Guilin Jinma, a wholly-owned subsidiary of the company, signed a “M&A Intent Agreement” with Eight Plus One Pharmaceutical to acquire its controlling interest. Eight Plus One Pharmaceuticals has 23 drug development patents and 3 clinical approvals for Class 1 new drugs. The due diligence period is 60 days, and the exclusive period is 90 days. The transaction consideration is subject to negotiation, and subsequent decision-making and approval procedures must be carried out. The target company has unresolved execution cases, there is uncertainty about the listing of products under development, and there are many uncertainties about this merger and acquisition.

Tonghua Jinma announced that on August 6, 2026, Guilin Jinma, a wholly-owned subsidiary of the company, signed a “M&A Intent Agreement” with Eight Plus One Pharmaceutical to acquire its controlling interest. Eight Plus One Pharmaceuticals has 23 drug development patents and 3 clinical approvals for Class 1 new drugs. The due diligence period is 60 days, and the exclusive period is 90 days. The transaction consideration is subject to negotiation, and subsequent decision-making and approval procedures must be carried out. The target company has unresolved execution cases, there is uncertainty about the listing of products under development, and there are many uncertainties about this merger and acquisition.